Search
- May 9
Ascidian presented NHP and human retinal explant data at #ASGCT2024 suggesting proof of concept for its RNA exon editing approach
Head of research Robert Bell described the preclinical data in a Stargardt disease model that has led to an IND acceptance for this...
- Jan 29
The Science Behind the News: Ascidian Therapeutics' IND is cleared for an RNA exon editing program against Stargardt disease
Ascidian Interim President & CEO Mike Ehlers explains the scientific concept of RNA exon editing